Meeting
2020 Genitourinary Cancers Symposium
Efficacy of sequential therapy comprising of docetaxel, abiraterone, enzalutamide, and cabazitaxel in patients with castration-resistant prostate cancer.
Authors
Akiyuki Yamamoto
Department of Urology, Toyohashi Municipal Hospital, Toyohashi City, Japan
Akiyuki Yamamoto , Masashi Kato , Toyonori Tsuzuki , Momokazu Gotoh , Yushi Naito , Kyosuke Hattori , Kosuke Tochigi , Takuma Yuba , Hideji Kawanishi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 239)
Abstract #
239
Poster Bd #
B17
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Exploring optimal sequence of abiraterone and enzalutamide in patients with castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
First Author: Naoki Terada
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova
Poster
2020 Genitourinary Cancers Symposium
Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.
First Author: Giorgia Gurioli
Poster
2017 ASCO Annual Meeting
Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Constance Thibault